Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13558662 | 0.96 | CXCR4 (0.43) | CXCR4KCNK3NPC1RAB9AALDH1A1 | |
| SCHEMBL12643789 | 0.85 | CXCR4 (0.42) | CXCR4ALDH1A1MAPTPRMT5WDR77 | |
| SCHEMBL14213448 | 0.85 | CXCR4 (0.42) | CXCR4ALDH1A1MAPTPRMT5WDR77 | |
| SCHEMBL2603271 | 0.85 | CXCR4 (0.42) | CXCR4ALDH1A1MAPTPRMT5WDR77 | |
| SCHEMBL2603276 | 0.81 | CXCR4 (0.43) | CXCR4NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL2603290 | 0.80 | CXCR4 (0.42) | CXCR4NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL22871227 | 0.78 | CHRNB2 (0.53) | — | |
| SCHEMBL17114327 | 0.77 | CXCR4 (0.40) | CXCR4ALDH1A1PRMT5WDR77 | |
| SCHEMBL17114328 | 0.77 | CXCR4 (0.40) | CXCR4ALDH1A1PRMT5WDR77 | |
| SCHEMBL327871 | 0.77 | CXCR4 (0.53) | CXCR4HRH3NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | CXCR4 3376/4885KCNK3 3540/4885HRH3 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.